NCT07064759

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 480 (estimated)
• Sponsor: 4D Molecular Therapeutics · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Conditions

• Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

Type	Name	Description
BIOLOGICAL	4D-150 IVT (3E10 vg/eye)	If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
BIOLOGICAL	EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Eylea (aflibercept) will be administered at applicable visits

Timeline

• Start date: 2025-07-22
• Primary completion: 2028-11-01
• Completion: 2029-02-01
• First posted: 2025-07-15
• Last updated: 2026-04-16

Locations

94 sites across 14 countries: United States, Argentina, Australia, Bulgaria, Germany, Hungary, Italy, Japan, Latvia, Lithuania, Portugal, Singapore, Spain, United Kingdom

Regulatory

• FDA-regulated drug study